Systemic therapy of atopic dermatitis in children and adults

Simon, Dagmar (2011). Systemic therapy of atopic dermatitis in children and adults. Current problems in dermatology, 41, pp. 156-164. Basel: Karger 10.1159/000323309

Full text not available from this repository. (Request a copy)

Systemic therapy is required in patients with severe atopic dermatitis (AD) refractory to adequate topical therapy. The aim of a systemic therapy is the rapid and efficient improvement of skin symptoms and pruritus in acute exacerbation and/or the long-term control of severe chronic disease. A number of immunosuppressive and immunomodulating substances are available that may efficiently reduce skin inflammation and thus lead to a relief of symptoms including pruritus. The excellent effects of cyclosporine as short-term as well as maintenance therapy have been documented in several studies in children and adults. Furthermore, other immunosuppressive substances such as azathioprine, mycophenolate mofetil and methotrexate are effective in patients with moderate to severe AD. Intravenous immunoglobulins and γ-interferon exert immunomodulatory effects and thus may improve severe AD. Biological agents are a new approach in AD therapy since they may specifically target cells, cytokines or mediators involved in the pathogenesis of AD.

Item Type:	Journal Article (Further Contribution)
Division/Institute:	04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology
UniBE Contributor:	Simon, Dagmar
ISSN:	0070-2064
Publisher:	Karger
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:21
Last Modified:	05 Dec 2022 14:06
Publisher DOI:	10.1159/000323309
PubMed ID:	21576956
Web of Science ID:	000291366400013
URI:	https://boris.unibe.ch/id/eprint/7082 (FactScience: 212233)